-
Media ReleaseApproximately 80% of psoriatic arthritis patients treated with Cosentyx® saw no progression of joint damage as shown in Novartis new two-year observational data
-
Media ReleaseFDA approves new Novartis dual combination bronchodilator Utibron™ Neohaler® for patients with chronic obstructive pulmonary disease
-
Media ReleaseNovartis announces new CTL019 study data demonstrating overall response in adult patients with certain types of lymphoma
-
Media ReleaseNovartis Pharmaceuticals Corporation finalizes settlement agreement resolving civil suit filed by the U.S. Attorney’s Office for the Southern District of New York
-
Media ReleaseNovartis heart failure medicine Entresto™ substantially cuts 30-day hospital readmissions, new post-hoc analysis shows
-
Media ReleaseNovartis receives two new FDA approvals for Cosentyx® (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis
-
Media ReleaseNovartis announces publication of two landmark studies in NEJM demonstrating efficacy of Cosentyx® in patients with ankylosing spondylitis
-
Media ReleaseNovartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL
-
Media ReleaseNew analyses show Novartis' Entresto™ reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction (HFrEF) regardless of prior heart failure hospital admissions or background therapy
-
Media ReleaseNew Novartis data show Cosentyx demonstrated sustained superiority in skin clearance (PASI 90) versus Stelara at Week 52
-
Media ReleaseFDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors (NET)
-
Media ReleaseMedia Statement: Leading US cardiology societies strongly recommend Entresto® as a new standard of care treatment in an earlier-than-expected joint update of clinical practice guidelines for heart failure